Form 4: Theriva Biologics CEO and CFO Acquires Stock Options
SEC Form 4
Steven A. Shallcross, CEO and CFO of Theriva Biologics, Inc., reports the acquisition of stock options.
Summary
- Steven A. Shallcross, the CEO and CFO of Theriva Biologics, Inc. (TOVX), filed a Form 4.
- The filing reports the acquisition of 190,000 stock options with an exercise price of $1.4144.
- The options were granted on April 29, 2025, and vest pro rata on a monthly basis over 36 months, expiring on April 29, 2032.
- Following the transaction, Shallcross directly owns 190,000 derivative securities.
Sentiment
Score: 6
Explanation: The sentiment is neutral. It's a routine disclosure of stock option grants, which is neither overwhelmingly positive nor negative.
Positives
- The CEO's acquisition of stock options could be seen as a positive sign, indicating confidence in the company's future performance.
Industry Context
This is a standard SEC filing related to executive compensation. Stock options are a common form of executive compensation in the biotechnology industry.
Comparison to Industry Standards
- Stock option grants are a typical component of executive compensation packages in the biotech industry.
- Companies like Amgen, Gilead, and Biogen also utilize stock options to incentivize their executives.
- The vesting schedule of 36 months is also fairly standard.
Key Dates
| Date | Description |
|---|---|
| 04/29/2025 | Date of earliest transaction and grant date of stock options. |
| 05/01/2025 | Date of signature. |
| 04/29/2032 | Expiration date of the stock options. |
Keywords
stock options, Form 4, Theriva Biologics, TOVX, Steven A. Shallcross, CEO, CFO, beneficial ownership, acquisition
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.